OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Psychopharmacology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Signatures of exposure to childhood trauma in young adults in the structure and neurochemistry of the superior temporal gyrus	255
Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review	180
Clozapine-specific proliferative response of peripheral blood-derived mononuclear cells in Japanese patients with clozapine-induced agranulocytosis	103
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	86
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	72
Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review	67
Psychedelics and the ‘inner healer’: Myth or mechanism?	63
D₂-like receptor activation by intranasal dopamine attenuates fear responses induced by electrical stimulation of the dorsal periaqueductal grey matter, but fails to reduce aversion to pit	56
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?	54
Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered st	53
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins	52
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	49
Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction	48
Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review	48
Exploring the effects of erythropoietin treatment on cortical thickness and hippocampal volume in patients with mood disorders undergoing electroconvulsive therapy: A randomized, placebo-controlled tr	45
The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review	41
Benzodiazepines for PTSD: Poor data quality and misleading advice	39
The dosing procedure that “makes the poison”: Comparing the effects of single versus cumulative alcohol administration methods on emotion recognition	39
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review	39
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	38
Association of cannabis use with neurocognition in adolescents with bipolar disorder	38
Aripiprazole for treating delirium: A systematic review—Is it a valid yet understudied treatment?	36
Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks	34
Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial	34
Driving performance and ocular activity following acute administration of 10 mg methylphenidate: A randomised, double-blind, placebo-controlled study	34

A single injection of neuropeptide QRFP in the lateral hypothalamus decreased food intake	33
Neural correlates of episodic memory decline following electroconvulsive therapy: An exploratory functional magnetic resonance imaging study	32
Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function	32
5-HT_1B receptor agonist attenuates cocaine self-administration after protracted abstinence and relapse in rats	31
An efficient and label-free LC-MS/MS method for assessing drug’s activity at dopamine and serotonin transporters using transporter-transfected HEK293T cells	31
Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: A randomized controlled trial	30
From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions	30
A letter to the editor, associated with the article entitled “Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketam	30
Adult rat ultrasonic vocalizations and reward: Effects of propranolol and repeated cocaine administration	29
Associations of treatment with hypnotics with suicide and attempted suicide: A nationwide cohort study	29
Catechol-O-methyltransferase activity does not influence emotional processing in men	28
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine	27
Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness	26
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	25
Episodic foresight is impaired following acute alcohol intoxication	25
Challenges for switching central nervous system and psychiatric medication products: A review of the literature	25
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression	24
The chronic effects of a combination of herbal extracts (Euphytose^®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	23
Effects of positive mGlu5 modulation on D₂ signaling and nicotine-conditioned place preference: Mechanisms of epigenetic inheritance in a transgenerational model of drug abuse vulnerability	23
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis	21
Time-dependent association between selective serotonin reuptake inhibitors and hospitalization due to hyponatremia	21
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice	21
Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study	20
‘Memory, hither come’: Psychopharmacology of memory and more	20
Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials	20
Body mass index, waist circumference, insulin, and leptin plasma levels differentiate between clozapine-responsive and clozapine-resistant schizophrenia	20
Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis	20
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	19
The history of clozapine in clinical practice: From its introduction to a guideline proposing personalized titrations	19
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	19
Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review	18
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	18
Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement	18
Psychedelics: Old drugs, new trips	18
Antipsychotics, the heartland of clinical psychopharmacology?	18
The relation between naturalistic use of psychedelics and perception of emotional stimuli: An event-related potential study comparing non-users and experienced users of classic psychedelics	18
Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database	18
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	17
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	17
Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being	17
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	17
Translational psychopharmacology	17
Relationship between depression, prefrontal creatine and grey matter volume	17
Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial	16
Lifetime classic psychedelic use and headaches: A cross-sectional study	16
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis	15
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	15
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	15
Evaluating the efficacy of metformin in reducing hyperprolactinemia among patients with schizophrenia: A meta-analysis of randomized controlled trials	14
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	14

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	14
The anti-inflammation pharmacodynamics of lithium: Therapy of bipolar disorder	14
Individual differences in cocaine-induced conditioned place preference in male rats: Behavioral and transcriptomic evidence	14
Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies	14
Hyodeoxycholic acid inhibits lipopolysaccharide-induced microglia inflammatory responses through regulating TGR5/AKT/NF-κB signaling pathway	14
A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression	14
Responses to clinical treatment of bipolar versus unipolar depressive episodes in women versus men	13
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	13
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	13
Altered cerebellar-cortical resting-state functional connectivity in cannabis users	13
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial	13
Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction	13
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	13
Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment	13
Cognitive impairment in schizophrenia is associated with prefrontal–striatal functional hypoconnectivity and striatal dopaminergic abnormalities	13
Belief changes associated with psychedelic use	13
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	12
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ)	12
Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials	12
Habitual caffeine intake, genetics and cognitive performance	12
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study	12
Dopaminergic and noradrenergic modulation of stress-induced alterations in brain activation associated with goal-directed behaviour	12
Repurposing psychopharmacology: A two-way street?	12
Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression	12
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	12
Sweet-liking and sugar supplementation as innovative components in substance use disorder treatment: A systematic review	12
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	11
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	11
The impact of cannabidiol placebo on responses to an acute stressor: A replication and proof of concept study	11
Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials	11
Commentary: A framework for assessment of adverse events in psychedelic research	11
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)	11
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	11
The NK1 antagonist L-733,060 facilitates sequence learning	11
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder	11
Enhanced responsiveness to hypoxic panicogenic challenge in female rats in late diestrus is suppressed by short-term, low-dose fluoxetine: Involvement of the dorsal raphe nucleus and the dorsal periaq	11
Equasy revisited	11
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults	11
Common protein networks for various drug regimens of major depression are associated with complement and immunity	10
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response	10
Impaired face symmetry detection under alcohol, but no ‘beer goggles’ effect	10
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	10
Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial	10
Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis	10
The biologically active compound of Withania somnifera (L.) Dunal, docosanyl ferulate, is endowed with potent anxiolytic properties but devoid of typical benzodiazepine-like side effects	10
Associative memory in alcohol-related contexts: An fMRI study with young binge drinkers	9
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	9
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	9
Do antipsychotic drugs shrink the brain? Probably not	9
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study	9
GABAergic modulation of performance in response inhibition and interference control tasks	9
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	9
The Journal of Psychopharmacology: La Plus ça change. . .	9
Neurostructural and neurocognitive correlates of APOE ε4 in youth bipolar disorder	9
Ketamine: Therapeutic potential versus recreational misuse	9
Alprazolam-related deaths in Scotland, 2004–2020	9
Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review	9
Bench, bedside, and balance	9
The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls	9
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	9
Behavioral profile of adult zebrafish acutely exposed to a selective dopamine uptake inhibitor, GBR 12909	9
MDMA enhances positive affective responses to social feedback	9
Psilocybin’s effects on cognition and creativity: A scoping review	9
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	9